PathGroup Moving Toward 100% Digital Pathology

Laboratory Economics‘ Jondavid Klipp spoke with Concentriq Dx* user Derek Welch, MD, Chief Medical Officer and Executive Vice-President at PathGroup. In the Q&A, Dr. Welch speaks to PathGroup’s progress in achieving 100% digitization and the benefits it has seen thus far. From helping pathologists to move more quickly from slide to slide and between cases to speeding up turnaround time and enabling almost real-time sharing of cases, digital pathology has driven meaningful efficiencies for PathGroup.

*Concentriq Dx is CE-marked under IVDR and is available for primary diagnosis in the US under the COVID-19 enforcement policy for remote pathology devices.